CIK 0001393434
- Large accelerated filer
OCULAR THERAPEUTIX, INC
Sign in to watch- Ticker
- OCUL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 781-357-4000
- Business address
- 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
- Former names
- I-THERAPEUTIX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $799,174
- in 9 filings, $788K under 10b5-1 plans
Net −$799,174. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dugel Pravin −$233K Reporting owner sold <1% of stake
- Saroj Namrata −$232K Chief Business Officer sold 14% of stake
- Heier Jeffrey S. −$112K Chief Scientific Officer sold 4% of stake
- Kaiser Peter −$103K Chief Development Officer sold 5% of stake
- Anderman Todd −$87K Chief Legal Officer sold 8% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-02-05 | Hanley Kevin F. Senior V.P.,Tech Operations | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2018-01-31 | Goldstein Michael H. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +83,500 | 83,500 | ||
| 2018-01-31 | Bollag Daniel M | Grant or award · Stock Option (Right to Buy) | +51,100 | 51,100 | ||
| 2018-01-31 | Notman Donald Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +83,500 | 83,500 | ||
| 2018-01-31 | Mattessich Antony C. President and CEO | Grant or award · Stock Option (Right to Buy) | +360,000 | 360,000 | ||
| 2018-01-31 | Sawhney Amarpreet Exec Chairman of the Board | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2017-12-21 | Sawhney Amarpreet Exec Chairman of the Board | Exercise or conversion | +83,011 | $2.49 | $207K | 779,401 |
| 2017-12-21 | Sawhney Amarpreet Exec Chairman of the Board | Exercise or conversion | +106,382 | $2.73 | $290K | 885,783 |
| 2017-12-21 | Sawhney Amarpreet Exec Chairman of the Board | Exercise or conversion · Stock Option (Right to Buy) | −83,011 | 0 | ||
| 2017-12-21 | Sawhney Amarpreet Exec Chairman of the Board | Exercise or conversion · Stock Option (Right to Buy) | −106,382 | 0 | ||
| 2017-12-12 | Mattessich Antony C. President and C.E.O. | Purchase | +21,000 | $4.29 | $90K | 21,000 |
| 2017-12-07 | Notman Donald Chief Financial Officer | Purchase | +4,800 | $4.00 | $19K | 4,800 |
| 2017-12-06 | Bollag Daniel M | Purchase | +24,700 | $3.93 | $97K | 24,700 |
| 2017-11-16 | Sawhney Amarpreet Exec. Chairman of the Board | Purchase | +19,000 | $5.18 | $98K | 696,390 |
| 2017-10-02 | Goldstein Michael H. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2017-10-02 | Notman Donald Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2017-08-07 | Bollag Daniel M | Grant or award · Stock Option (Right to Buy) | +110,000 | 110,000 | ||
| 2017-06-20 | Mattessich Antony C. Director | Grant or award · Stock Option (Right to Buy) | +590,000 | 590,000 | ||
| 2017-06-01 | GARVEY JAMES M Director | Grant or award · Stock Option (Right to Buy) | +13,500 | 13,500 | ||
| 2017-06-01 | Chadha Jaswinder Director | Grant or award · Stock Option (Right to Buy) | +13,500 | 13,500 |
Page 19 of 27 · 522 trades